Targeted PARP inhibitors in advanced ovarian cancer "higher care value"

  • PDF / 169,725 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 27 Downloads / 209 Views

DOWNLOAD

REPORT

1173-5503/20/0861-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 5 Sep 2020 No. 861

1

Data Loading...

Recommend Documents
Recommendations for CEAs of PARP inhibitors for ovarian cancer

160 90 184KB

PARP Inhibitors for Cancer Therapy

169 99 16MB

The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer

145 0 810KB

Targeted Therapies in Advanced Gastric Cancer

182 71 321KB

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

139 81 770KB

Prognostic Nutrition Index and Its Significance in Advanced Ovarian Cancer

171 49 226KB

Correction to: Outcome quality standards in advanced ovarian cancer surgery

183 92 191KB

Outcome quality standards in advanced ovarian cancer surgery

147 97 756KB

The progress of targeted therapy in advanced gastric cancer

150 40 185KB

Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer

146 30 687KB

STAT Inhibitors in Cancer

162 112 5MB

Olaparib cost effective for advanced BRCA -associated ovarian cancer

145 30 168KB